01-12-2023 | Epstein-Barr Virus | Case report
Cyclophosphamide/Fludarabine/Rituximab
Cytomegalovirus infection reactivation and Epstein-Barr virus infection reactivation following off-label use
Published in: Reactions Weekly | Issue 1/2023
Login to get accessExcerpt
Author Information-
* death
-
* life-threatening
-
* hospitalisation
-
* disability
-
* congenital anomaly
-
* other medically important event